Browsed by
Tag: medicine & surgery

Nicotine Patch, Nicotine Gum And – Tablets: To Defeat The Addiction?

Nicotine Patch, Nicotine Gum And – Tablets: To Defeat The Addiction?

Almost every smoker will be tried at least once to quit smoking and therefore know how difficult that can be. Nicotine replacement in the form of nicotine gum, nicotine patches or nicotine tablets promises relief of withdrawal symptoms, but it can also work? Tools that are designed to help a smoker in the fight against the smoke there are many. Everyone must find out individually on the basis of his smoking behaviour, which promise for him the best chance of success. In addition to books, herbal and electronic cigarettes, nicotine nasal spray, there is also nicotine patches, nicotine gum, and tablets. What is nicotine? Nicotine is an alkaloid and neurotoxin, which occurs in the tobacco plant. Is lit a cigarette and thus also included tobacco, nicotine is released and concluded with the smoke and tied to tiny particles of tar in the lungs and into the blood. Normally, the blood-brain barrier keeps toxins so that they reach not the brain. Unlike the neurotoxin nicotine: nicotine molecules reach a short time after the move to a cigarette the brain, on nerve cells and can alter so their activity.

This is done through the distribution of chemicals, such as serotonin, endorphins, norepinephrine and dopamine, because these are the exchange of information between the individual nerves. Already a cigarette can be enough to notice symptoms of nicotine withdrawal to first physical withdrawal symptoms. It comes to concentrating, irritability and anxiety. Depending on how many cigarettes it has consumed as smoking, physical dependency symptoms after quitting as head pain, circulatory problems, nervousness and sweating. The temporary slowdown of metabolism can cause weight gain. The fact that nicotine stimulates the body’s reward system while smoking, it may remain the permanent supply of nicotine to bad mood with aggressiveness and irritability, are concentration and even depression. The fact that this state several weeks and Last months, is to blame for this, that so many smokers do not create withdrawal and start smoking again.

How do nicotine replacement products? Nicotine substitutes replace, as the name implies, for the time being the narcotic nicotine, at the the body in the course of smoking life has got accustomed to. Physical withdrawal symptoms and a strong desire for a cigarette should be mitigated by the dose nicotine delivery. Nicotine patches are glued directly onto the skin and there to deliver the nicotine. Nicotine gum and nicotine tablets, recorded the nicotine via the mucous membranes and supplies the body with the fabric. There are of different thicknesses, which gradually reduces the supply of nicotine replacement drugs. As with cigarettes, nicotine is delivered to the body but no other cancer-causing toxins such as carbon monoxide or tar. For more information, as well as offers for nicotine replacement products, see

InterMune

InterMune

The first approved drug for the treatment of idiopathic pulmonary fibrosis offers European patients new hope BASEL, Switzerland, March 3, 2011 – InterMune, Inc. (NASDAQ: ITMN) today announced that the European Commission (EC) has granted approval for Esbriet (Pirfenidon). Esbriet for doing this is indicated for the treatment of adults with mild to moderate idiopathic pulmonary fibrosis (idiopathic pulmonary fibrosis, IPF), a progressive fatal lung disease. Walton Family Foundation gathered all the information. With the approval of the sales is approved by Esbriet in all 27 EU Member States, which represents a major turning point in the treatment of more than 100,000 IPF patients in Europe. InterMune is proud to be able to offer the first drug for IPF patients in Europe with Esbriet”, so Dan Welch, Chairman, Chief Executive Officer and President of InterMune. The admission of Esbriet is not only a historic moment in the treatment of IPF patients, for which so far was no approved drug therapy available.

But It is also an exciting new chapter for our company, because we are an international organization so that. Our experienced management team in the EU is working very intensively to provide Esbriet European patients as quickly as possible.” InterMune is planning the launch of Esbriet according to the schedule of the normal approval and reimbursement procedures in the various Member States of the EU. The first launch is expected for 2011. Roland you Bois, MD, Professor of Pulmonology at Imperial College in London and co Chairman of the clinical phase III program for Esbriet, explained: at the IPF is a chronic and progressive respiratory disease with an estimated survival rate of only 20 percent after five years. as a result it is more lethal than many types of cancer. However, are approved in Europe to this day no therapeutic interventions for the treatment of patients who suffer from this devastating disease. The approval of this new drug is for the European patients a milestone in treating IPF.